Key Highlights

• CSL has entered an exclusive agreement with Alentis Therapeutics to co-develop lixudebart, a potential first-in-class treatment for rare kidney and liver diseases.

• CSL will make an initial payment of US$355 million, with Alentis eligible for up to an additional US$1.2 billion in commercial milestones.

• Global profits will be shared 55% to CSL and 45% to Alentis upon commercialisation.

CSL Ltd (ASX:CSL) closed at A$202.40 on 05 November 2026, rising 2.56% during the session. The S&P/ASX 200 (XJO) advanced 2.61%, adding 230.60 points to reach 9,065.10, while the S&P/ASX 200 Health Care index (XHJ) gained 3.64%, climbing 1,240.30 points to 35,329.10. The gains were supported by overnight Wall Street advances following the Democrats' decisive victory in the U.S. midterm elections. CSL is a global biotechnology company headquartered in Melbourne, with operations spanning plasma-derived therapies, vaccines, and an expanding portfolio of novel treatments.

Exclusive Agreement with Alentis Therapeutics

On 5 October 2026, CSL announced it had entered into an agreement with Alentis Therapeutics to co-develop and co-promote lixudebart, described as a potential first-in-class treatment for people with rare kidney and liver diseases. Lixudebart is an investigational monoclonal antibody that selectively targets exposed claudin-1, a key driver of inflammatory and fibrotic signalling pathways in multiple organ systems.

CSL will make an initial payment of US$355 million to Alentis, with the Swiss biotech eligible to receive up to an additional US$1.2 billion in commercial milestone payments. CSL will fully fund the completion of the ongoing Phase 2 RENAL trial and planned Phase 3 trial in ANCA-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN), as well as Phase 2 trials in focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis (PSC). Upon commercialisation, global profits will be shared 55% to CSL and 45% to Alentis.

Clinical Pipeline and Early Data

Lixudebart is currently being evaluated in the ongoing Phase 2 RENAL trial in patients with AAV-RPGN, a rare and potentially life-threatening autoimmune disease that can cause irreversible kidney damage and end-stage renal disease. In an interim analysis of 26 patients, lixudebart showed improvement in kidney function as assessed by eGFR and proteinuria at 24 weeks. In the Phase 1b FEGATO trial in 41 patients with advanced liver fibrosis, the drug demonstrated improved liver function at six weeks. Both studies showed dose-dependent target engagement and a favourable safety profile.

Dr Bill Mezzanotte, Executive Vice President and Head of R&D at CSL, noted the collaboration reflects CSL's commitment to building a leading global nephrology Franchise and its strategic intent to create high-value external partnerships.

About the Company

CSL Limited is one of the world's largest biotechnology companies, with a heritage spanning over a century. The company operates across three main Business lines: CSL Behring (plasma-derived and recombinant therapies), CSL Seqirus (influenza vaccines), and CSL Vifor (iron deficiency and nephrology). CSL employs approximately 32,000 people globally and its products are available in more than 100 countries.

Sector Context

The ASX healthcare sector posted gains on 05 November 2026, with the Health Care index rising 3.64%. CSL's 2.56% gain was slightly below the sector benchmark. As one of the largest companies on the ASX by market capitalisation, CSL's performance carries significant weighting within the health care index. The company's move into nephrology through the Alentis Partnership signals continued expansion beyond its traditional plasma franchise.

Risks

Drug development carries inherent risks, and lixudebart remains in Clinical Trials with no guarantee of regulatory approval. The US$355 million upfront payment represents a significant capital commitment. Competition in the nephrology and rare disease space continues to intensify from both established pharmaceutical companies and emerging biotech firms. Foreign exchange movements, particularly in the AUD/USD pair, affect CSL's reported Earnings given its predominantly overseas Revenue base.

Catalysts on Watch

Results from the Phase 2 RENAL trial in AAV-RPGN will be a key data readout. Initiation of Phase 2 trials in FSGS and PSC will expand the clinical program's scope. Progress toward Phase 3 trial design and any regulatory interactions regarding lixudebart's development pathway will also be monitored. CSL's broader pipeline milestones across its therapeutic portfolio continue to represent potential catalysts.

The Broader Picture

CSL's exclusive agreement with Alentis Therapeutics represents a significant step in the company's strategy to build a nephrology franchise. The US$355 million upfront payment and potential US$1.2 billion in commercial milestones underscore the scale of the commitment. With early clinical data showing signals of kidney function improvement, the focus now shifts to advancing trials across multiple rare disease indications.